Several pharmacophores including thiophene sulfonamides, ethylidene hydrazine yl thiazolones, and 4‐(2‐arylidene hydrazine yl)thienopyrimidines have exhibited promising VEGFR‐2 inhibitory activity, disrupting tumor vascularization and impairing cancer cell proliferation [17, 31]. The gene discussed is KDR; the disease is neoplasm.